6.47

0.15% -0.01

Pre-market: 6.55 0.08 +1.24%

Sagimet Biosciences Inc (SGMT)

Overview News Price History Discussions Forecast

Sagimet Biosciences Inc stock is traded at $6.47, with a volume of 605.46K. It is down -0.15% in the last 24 hours and down -6.23% over the past month. Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.

Previous Close:

$6.48

Open:

$6.56

24h Volume:

605.46K

Relative Volume:

0.42

Market Cap:

$399.53M

Revenue:

$2.00M

Net Income/Loss:

$-43.51M

P/E Ratio:

-4.823

EPS:

-1.3415

Net Cash Flow:

$-39.73M

1W Performance:

-0.92%

1M Performance:

-6.23%

6M Performance:

+7.30%

1Y Performance:

-21.77%

1-Day Range:

$6.45

$6.7101

1-Week Range:

$6.32

$6.7472

52-Week Range:

$4.50

$11.41

Sagimet Biosciences Inc Stock (SGMT) Company Profile

Name

Sagimet Biosciences Inc

Sector

Healthcare (1104)

Industry

Biotechnology (621)

Phone

(650) 561-8600

Address

155 BOVET RD., SUITE 303, SAN MATEO

Employee

Twitter

Next Earnings Date

2026-05-14

Latest SEC Filings

SGMT's Discussions on Twitter

Compare SGMT vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SGMT Sagimet Biosciences Inc	6.47	399.53M	2.00M	-43.51M	-39.73M	-1.3415
VRTX Vertex Pharmaceuticals Inc	450.46	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.98	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	884.20	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	287.80	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	160.06	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-26-26	Initiated	Rodman & Renshaw	Buy
Feb-03-26	Initiated	Guggenheim	Buy
Jan-28-26	Initiated	Barclays	Equal Weight
Aug-11-25	Initiated	Wedbush	Outperform
Aug-07-25	Resumed	H.C. Wainwright	Buy
Jul-24-25	Initiated	Canaccord Genuity	Buy
Dec-06-24	Initiated	Oppenheimer	Outperform
Nov-12-24	Initiated	UBS	Buy
Jun-28-24	Downgrade	Goldman	Buy → Neutral
May-02-24	Initiated	H.C. Wainwright	Buy
Mar-25-24	Initiated	Leerink Partners	Outperform
Aug-08-23	Initiated	Goldman	Buy
Aug-08-23	Initiated	JMP Securities	Mkt Outperform
Aug-08-23	Initiated	Piper Sandler	Overweight
Aug-08-23	Initiated	TD Cowen	Outperform

View All

Sagimet Biosciences Inc Stock (SGMT) Latest News

Jun 15, 2026

Sagimet Biosciences (SGMT) director receives 39,567 stock options grant - Stock Titan

Jun 15, 2026

Sagimet Biosciences (SGMT) director receives stock option grant for 39,567 shares - Stock Titan

Jun 15, 2026

Director at Sagimet Biosciences (NASDAQ: SGMT) receives 39,567 stock options - Stock Titan

Jun 15, 2026

Sagimet Biosciences (SGMT) director receives 39,567 stock options at $6.48 - Stock Titan

Jun 15, 2026

Sagimet Biosciences (SGMT) grants director Kemble George 39,567 stock options - Stock Titan

Jun 15, 2026

Director Anne Phillips receives 39,567 Sagimet (SGMT) stock options at $6.48 strike - Stock Titan

Jun 15, 2026

Jun 12, 2026

Sagimet Biosciences Announces Board Changes and Director Elections - TipRanks

Jun 12, 2026

Tim Walbert resigns from Sagimet's board - TradingView

Jun 12, 2026

Sagimet Biosciences (SGMT) director resigns as shareholders elect Board, ratify KPMG - Stock Titan

Jun 12, 2026

Sagimet Biosciences Inc. Announces Resignation of Tim Walbert as Member of the Board of Directors, Effective as of June 12, 2026 - marketscreener.com

Jun 12, 2026

Jun 11, 2026

Certain Restricted Stock Units of Sagimet Biosciences Inc. are subject to a Lock-Up Agreement Ending on 12-JUN-2026. - marketscreener.com

Jun 11, 2026

Jun 08, 2026

SGMT Stock Surged 40% And Breached 200-DMA For The First Time In Nearly 3 Months – What’s Got Retail Buzzing? - Stocktwits

Jun 08, 2026

Here's Why Sagimet Biosciences Inc. (SGMT) Could be Great Choice for a Bottom Fisher - MSN

Jun 08, 2026

Jun 03, 2026

Sagimet Biosciences Grants New Performance-Based Executive Equity Awards - TipRanks

Jun 03, 2026

[8-K] Sagimet Biosciences Inc. Reports Material Event - Stock Titan

Jun 03, 2026

Sagimet Biosciences (SGMT) Slides 1.99% as Stock Approaches Key Support ZoneCalendar Spread Trade - newsline.com

Jun 03, 2026

Jun 01, 2026

Sagimet Biosciences (SGMT) grants CEO options on 300,000 shares - Stock Titan

Jun 01, 2026

Sagimet (SGMT) CFO receives 50,000 options at $7.27 exercise price - Stock Titan

Jun 01, 2026

May 29, 2026